Calls Now Open

2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs

You've just added:

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

Posted on June 07, 2022

Scholar in the News

Spring 2022

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

Entry of the SARS-CoV-2 coronavirus, which causes COVID-19, requires a host serine protease called TMPRSS2. Camostat mesylate, an orally available serine protease inhibitor, inhibits TMPRSS2, supporting clinical trials to investigate its use in COVID-19.

"The use of innovative modeling by Harrington gave us new insights into how to use Camostat clinically."

- Donald Stanski, MD, Harrington Discovery Institute

Advisor, Therapeutics Development Center

"Our team at Harrington Discovery Institute has stimulated deep, rigorous and invaluable thinking about the development of our drug."

- Joseph Vinetz, MD, FACP, FIDSA, FASTMH, BS


Read the full article in Microbiology Spectrum

About the Scholar

Joseph Vinetz

Infectious Disease, Virology

Joseph Vinetz, MD

Yale University
2020 Harrington Award for Coronavirus

More about Joseph Vinetz